SCHEMBL1136294

SCHEMBL1136294

CCCOc1ccc(F)c2c(=O)c(-c3ccc(OC)cc3OC)c(C)[nH]c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.37
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA2 P47869 1/20 0.36
MAOA P21397 2/20 0.36
NR3C1 P04150 2/20 0.36
PGR P06401 2/20 0.36
NR3C2 P08235 2/20 0.36
AR P10275 2/20 0.36
PDE4D Q08499 1/20 0.35
MPO P05164 1/20 0.35
MGAM O43451 4/20 0.34
GAA P10253 4/20 0.34
SI P14410 4/20 0.34
MGAM2 Q2M2H8 4/20 0.34
CRHR1 P34998 2/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1136167 0.88 MAOB (0.39) MAOBMAOAMGAMGAASI
SCHEMBL1136104 0.82 PDE4D (0.37) MAOBGABRG2GABRB3GABRA2MAOA
SCHEMBL1136157 0.80 MAPK13 (0.39) MAOBMAOA
SCHEMBL1136250 0.79 HCRTR1 (0.39)
SCHEMBL1136308 0.78 MAOB (0.39) MAOBMAOAMGAMGAASI
SCHEMBL1136313 0.78 MAPK13 (0.32) GAA
SCHEMBL1136159 0.78 MAOB (0.36) MAOBMAOACRHR1MTNR1AMTNR1B
SCHEMBL1135964 0.77 MAOB (0.39) MAOBMAOAPDE4DMTNR1AMTNR1B
SCHEMBL1136189 0.77 MAOB (0.37) MAOBGABRG2GABRB3GABRA2MAOA
SCHEMBL1136363 0.77 MAOB (0.37) MAOBMAOAMGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160304461-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-10-20 US disclosed
US-9403773-B2 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-02 US disclosed
US-20150218101-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-08-06 US disclosed
US-9045464-B2 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-06-02 US disclosed
US-20140121207-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-01 US disclosed
US-8642619-B2 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
US-20120316168-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-12-13 US disclosed
US-8269011-B2 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-09-18 US disclosed
EP-2152699-B1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2011-02-23 EP disclosed
US-20100130546-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316168-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 MAOB 424/4885GABRG2 1744/4885GABRB3 878/4885
US-20140121207-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 MAOB 424/4885GABRG2 1744/4885GABRB3 878/4885
US-20160304461-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 MAOB 424/4885GABRG2 1744/4885GABRB3 878/4885
US-20100130546-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 MAOB 424/4885GABRG2 1744/4885GABRB3 878/4885
US-20150218101-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 MAOB 424/4885GABRG2 1744/4885GABRB3 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.